Trending NewsTrending NewsNASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis $4.26 -0.95 (-18.23%) Closing price 03:59 PM EasternExtended Trading$4.29 +0.03 (+0.80%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Savara Stock (NASDAQ:SVRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Savara alerts:Sign Up Key Stats Today's Range$4.00▼$4.5250-Day Range$4.22▼$5.4552-Week Range$4.00▼$7.01Volume17.01 million shsAverage Volume3.02 million shsMarket Capitalization$939.84 millionP/E RatioN/ADividend YieldN/APrice Target$10.14Consensus RatingModerate Buy Company Overview Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing. Molgramostim is investigational; its availability and development status may change as clinical and regulatory work progresses. Savara’s business is centered on advancing this program and evaluating its potential to address unmet needs in rare respiratory disease.AI Generated. May Contain Errors. Read More Savara Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreSVRA MarketRank™: 2.663358147225 of 5 starsSavara scored higher than 53% of companies evaluated by MarketBeat, and ranked 414th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingSavara has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialSavara has a consensus price target of $10.14, representing about 138.1% upside from its current price of $4.26.Amount of Analyst CoverageSavara has only been the subject of 4 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.68) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.59% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 12.94, which indicates bearish sentiment.Change versus previous monthShort interest in Savara has recently increased by 12.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.62 News SentimentSavara has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Savara this week, compared to 3 articles on an average week.Search Interest5 people have searched for SVRA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows12 people have added Savara to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SVRA Stock News HeadlinesSavara Says FDA Likely To Miss Molgramostim Review DeadlineNovember 20 at 3:05 PM | rttnews.comFDA Delays BLA Decision On Savara's Molgramostim For Lung Disease; Shares Drop 15%November 20 at 3:05 PM | rttnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 20 at 1:00 AM | Profits Run (Ad)SVRA stock hits 52-week low after FDA delays decision on lung disease drug applicationNovember 20 at 3:05 PM | msn.comFDA to miss deadline on Savara's rare lung disease drug approvalNovember 20 at 10:04 AM | reuters.comSavara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA DateNovember 20 at 10:04 AM | marketscreener.comMSavara (SVRA) Stock Looks Stretched As Its 338% Five Year Run ContinuesNovember 20 at 10:04 AM | finance.yahoo.comSavara Inc. (SVRA) Shares Are Taking Off. Here’s What’s ComingNovember 19 at 10:10 PM | insidermonkey.comSee More Headlines SVRA Stock Analysis - Frequently Asked Questions How have SVRA shares performed this year? Savara's stock was trading at $6.03 on January 1st, 2026. Since then, SVRA shares have decreased by 29.4% and is now trading at $4.26. How were Savara's earnings last quarter? Savara Inc. (NASDAQ:SVRA) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. Who are Savara's major shareholders? Savara's top institutional shareholders include Nantahala Capital Management LLC (3.24%), State Street Corp (3.01%), Marshall Wace LLP (2.89%) and Pictet Asset Management Holding SA (1.31%). Insiders that own company stock include Matthew Pauls, David L Lowrance, Joseph S Mccracken, Richard J Hawkins and Nevan C Elam. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some other companies that Savara investors own include NVIDIA (NVDA), Tesla (TSLA), Viking Therapeutics (VKTX), Solid Biosciences (SLDB), ADMA Biologics (ADMA), Cidara Therapeutics (CDTX) and Citius Pharmaceuticals (CTXR). Company Calendar Last Earnings11/09/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SVRA's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876Employees70Year Founded1995Price Target and Rating Average Price Target for Savara$10.14 High Price Target$12.00 Low Price Target$9.00 Potential Upside/Downside+138.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-96.87% Return on Assets-74.22% Debt Debt-to-Equity Ratio0.28 Current Ratio8.55 Quick Ratio8.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book8.69Miscellaneous Outstanding Shares220,620,000Free Float208,931,000Market Cap$939.84 million OptionableOptionable Beta0.32 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:SVRA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.